RARE Daily

JCR Enters Research Collaboration with Alexion

December 21, 2023

Rare Daily Staff

Japan’s JCR Pharmaceuticals has entered into a research collaboration, option and license agreement with Alexion, AstraZeneca Rare Disease for the development of novel oligonucleotide therapeutics to support targeted delivery to certain tissues or organs using JCR’s proprietary blood-brain barrier-penetrating technology.

J-Brain Cargo technology is JCR’s proprietary drug delivery system that efficiently delivers drugs to target tissues, including the central nervous system, through receptor-mediated transcytosis. It is applicable to various modalities including enzymes, oligonucleotides, lipid nanoparticles, gene and cell therapy, peptides, decoy receptors, and antibodies.

Under the terms of the agreement, JCR and Alexion will research and develop oligonucleotide therapeutics using JCR’s J-Brain Cargo Technology. As part of the collaboration, Alexion may nominate up to three targets in rare disease indications for pre-clinical development using the platform. Following pre-clinical development, Alexion will have the option to develop and commercialize the potential new drug candidates.

The collaboration is the second agreement between JCR and Alexion in 2023, following a March announcement regarding a research collaboration, option, and license agreement to develop therapeutic protein candidates using J-Brain Cargo for neurodegenerative disease.

JCR will receive an upfront payment from Alexion and has the right to receive certain research, development, and commercial milestones and royalties. The companies did not disclose specific financial terms.

“The agreement is another testament of the versatile applicability of the J-Brain Cargo Technology to different modalities and of JCR being a partner of choice for the development of biotherapeutics to support targeted delivery to certain tissues or organs,” said Shin Ashida, chairman and president of JCR Pharmaceuticals.




Stay Connected

Sign up for updates straight to your inbox.